Long-term effects of adding ovarian suppression to tamoxifen in young women
Part of Cancer, Skin clinical trials.
This study looks at the long-term health and outcomes of young women with hormone receptor-positive breast cancer who were part of an earlier trial. It compares women who received tamoxifen alone with those who also had their ovaries suppressed, to see if the combination offers better long-term results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who has not gone through menopause.
- You have a type of breast cancer that is hormone receptor-positive (fueled by hormones).
- You were part of the earlier ASTRRA study.
- Your doctors have long-term follow-up information about you.
- You have not had your uterus or both ovaries removed.
- You do not have a history of other cancers in the last 5 years (except certain skin cancers).
- You have not had a low platelet count or received a specific type of chemotherapy called CMF.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether taking hormone-blocking pills for longer than 5 years can help lower the risk of breast cancer returning. It is for people who had lymph node involvement and have already completed their initial 5-year treatment without the cancer coming back.
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This study follows women with breast cancer and certain lymphomas to understand long-term sexual and reproductive health. It may help researchers better support patients’ body changes and wellness over time during and after treatment.
This trial tests two low-dose hormone blockers (exemestane and tamoxifen) to see which one is better at preventing breast cancer in postmenopausal women who are at high risk. You will have a 50% chance of getting either drug, and the study will follow you for several years to compare their effectiveness and side effects.
This study looks at how a hormone called AMH changes during breast cancer treatment to help predict how well your ovaries are working as you approach menopause. It may help doctors better understand fertility and ovarian health for women in your situation.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.